Investment Thesis
Prelude Therapeutics exhibits unsustainable financial fundamentals with critical cash runway of <12 months at current burn rates. With operating cash flow of -21.7M against only 21.8M cash reserves and revenue of 4.6M, the company faces urgent near-term financing needs that create significant downside risk.
Strengths
- Revenue growth of 73.4% YoY demonstrates emerging commercial traction despite small base
- Zero debt with positive stockholders equity of 60.2M provides clean balance sheet
- Current and quick ratios of 2.03x indicate adequate near-term liquidity for operations
Risks
- Cash runway of approximately 12 months at current 21.7M annual operating burn rate requires imminent financing
- Operating loss of 14.2M on 4.6M revenue demonstrates severe unit economics and unprofitability
- Operating margin of -309% and net margin of -227% indicate business model is fundamentally challenged
Key Metrics to Watch
- Path to operating cash flow breakeven and burn rate reduction trajectory
- Revenue growth sustainability and achievement of positive gross margins on commercial products
- Cash position, financing announcements, and dilution from equity raises
Financial Metrics
Revenue
4.6M
Net Income
-10.4M
EPS (Diluted)
$-0.13
Free Cash Flow
-21.7M
Total Assets
119.6M
Cash
21.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-309.5%
Net Margin
-226.7%
ROE
-17.3%
ROA
-8.7%
FCF Margin
-473.5%
Balance Sheet & Liquidity
Current Ratio
2.03x
Quick Ratio
2.03x
Debt/Equity
0.00x
Debt/Assets
49.7%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T07:01:12.791807 |
Data as of: 2026-03-31 |
Powered by Claude AI